Cite
HARVARD Citation
Haas, M. et al. (2018). Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'. European journal of cancer. pp. 95-103. [Online].